Medline $MDLN Shares Sold by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. reduced its stake in Medline (NASDAQ:MDLN) by 2.7% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 795,551 shares of the company’s stock after selling 22,171 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned approximately 0.06% of Medline worth $27,606,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of MDLN. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Medline during the 3rd quarter worth $87,000. Vise Technologies Inc. acquired a new position in shares of Medline during the 3rd quarter valued at about $206,000. State of Wyoming grew its holdings in shares of Medline by 80.2% in the third quarter. State of Wyoming now owns 16,810 shares of the company’s stock valued at $583,000 after purchasing an additional 7,479 shares during the period. Choreo LLC purchased a new stake in shares of Medline in the third quarter valued at about $282,000. Finally, North Dakota State Investment Board grew its holdings in shares of Medline by 8.0% in the third quarter. North Dakota State Investment Board now owns 13,739 shares of the company’s stock valued at $477,000 after purchasing an additional 1,018 shares during the period.

Insider Buying and Selling at Medline

In related news, major shareholder Private Ltd Gic sold 2,570,999 shares of Medline stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $35.35, for a total value of $90,884,814.65. Following the completion of the sale, the insider owned 20,231,483 shares in the company, valued at approximately $715,182,924.05. This trade represents a 11.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last three months, insiders have sold 7,948,676 shares of company stock worth $281,805,137. Company insiders own 0.81% of the company’s stock.

Medline Trading Down 1.5%

Shares of MDLN stock opened at $39.76 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 4.33 and a quick ratio of 2.61. The firm has a market cap of $52.27 billion and a PE ratio of 33.35. The company has a 50-day moving average of $34.68 and a two-hundred day moving average of $39.51. Medline has a 1-year low of $31.37 and a 1-year high of $50.88.

Medline (NASDAQ:MDLN) last released its quarterly earnings results on Wednesday, November 4th. The company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.32 by $0.12. The business had revenue of $7.86 billion for the quarter. Medline had a net margin of 1.84% and a return on equity of 8.22%. On average, analysts predict that Medline will post 1.49 EPS for the current year.

Trending Headlines about Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Medline reported third-quarter EPS of $0.44, above the $0.32 consensus, on $7.86 billion in revenue. Reports also said the company raised its full-year growth outlook. Medline Q3 results
• Positive Sentiment: Several analysts raised price targets and maintained bullish ratings: UBS to $49, Citi to $47, and Leerink Partners to $46; BTIG reaffirmed Buy with a $55 target. These actions signal continued confidence in the stock’s potential. Read More., Read More., Read More., Read More.
• Positive Sentiment: Medline plans to raise prices in 2027 to help offset inflation, and reports cited a $1 billion share-buyback plan—both potential supports for financial performance and shareholder returns. Pricing and Q3 results
• Negative Sentiment: Despite the EPS beat, one report said quarterly profit fell, while Medline reaffirmed its full-year adjusted EBITDA outlook rather than raising it. That may have tempered the positive reaction to the results. Q3 profit and outlook report
• Negative Sentiment: A law firm announced an investigation into potential securities-fraud claims related to alleged product-quality issues. This is an allegation and investigation announcement, not a finding of wrongdoing, but it could add uncertainty for investors. Investigation announcement

Wall Street Analysts Forecast Growth

MDLN has been the topic of a number of analyst reports. Royal Bank Of Canada reduced their target price on shares of Medline from $53.00 to $46.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Tigress Financial dropped their price target on shares of Medline from $62.00 to $55.00 and set a “buy” rating for the company in a research note on Tuesday, August 11th. Evercore set a $39.00 price target on shares of Medline in a report on Thursday, August 6th. Deutsche Bank Aktiengesellschaft set a $37.00 price objective on Medline and gave the company a “hold” rating in a report on Thursday, August 6th. Finally, TD Cowen decreased their price objective on Medline from $53.00 to $45.00 and set a “buy” rating on the stock in a report on Monday, August 10th. Twenty-three investment analysts have rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Medline currently has a consensus rating of “Moderate Buy” and an average price target of $46.08.

About Medline

Medline Industries, Inc is a medical-supply manufacturer and distributor headquartered in Northfield, Illinois. The company provides products and supply-chain services to healthcare organizations, including hospitals, ambulatory surgery centers, physician offices, long-term care facilities, home health providers and other care settings.

Its product portfolio includes medical-surgical supplies, surgical and operating-room products, patient-care items, examination gloves, protective apparel, laboratory products, respiratory-care equipment, durable medical equipment and products for infection prevention.